These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11446848)

  • 1. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report.
    Biagiotti G; Cavallini G
    BJU Int; 2001 Jul; 88(1):63-7. PubMed ID: 11446848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease.
    Cavallini G; Biagiotti G; Koverech A; Vitali G
    BJU Int; 2002 Jun; 89(9):895-900. PubMed ID: 12010235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen versus placebo in the treatment of Peyronie's disease.
    Teloken C; Rhoden EL; Grazziotin TM; Ros CT; Sogari PR; Souto CA
    J Urol; 1999 Dec; 162(6):2003-5. PubMed ID: 10569556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological Management of Peyronie's Disease.
    Trost LW; Gur S; Hellstrom WJ
    Drugs; 2007; 67(4):527-45. PubMed ID: 17352513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study.
    Safarinejad MR; Hosseini SY; Kolahi AA
    J Urol; 2007 Oct; 178(4 Pt 1):1398-403; discussion 1403. PubMed ID: 17706714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy of Medical Treatment of Peyronie's Disease: Potassium Para-Aminobenzoate Monotherapy vs. Combination Therapy with Tamoxifen, L-Carnitine, and Phosphodiesterase Type 5 Inhibitor.
    Park TY; Jeong HG; Park JJ; Chae JY; Kim JW; Oh MM; Park HS; Kim JJ; Moon du G
    World J Mens Health; 2016 Apr; 34(1):40-6. PubMed ID: 27169128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic corticosteroid treatment in Peyronie's disease.
    Uzun H
    Med Hypotheses; 2013 Dec; 81(6):1029-30. PubMed ID: 24119766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical management of Peyronie's disease.
    Hellstrom WJ
    J Androl; 2009; 30(4):397-405. PubMed ID: 18974422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study.
    Pavone C; Napoli G; Caruana G; Alonge V; Usala M; Abbadessa D
    BJU Int; 2012 Jul; 110(1):117-21. PubMed ID: 22176734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical analysis of nonsurgical treatment of Peyronie's disease.
    Hauck EW; Diemer T; Schmelz HU; Weidner W
    Eur Urol; 2006 Jun; 49(6):987-97. PubMed ID: 16698449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease.
    Cavallini G; Modenini F; Vitali G
    Urology; 2007 May; 69(5):950-4. PubMed ID: 17482941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined intralesional interferon alpha 2B and oral vitamin E in the treatment of Peyronie's disease.
    Novak TE; Bryan W; Templeton L; Sikka S; Hellstrom WJ
    J La State Med Soc; 2001 Jul; 153(7):358-63. PubMed ID: 11519219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The treatment of Peyronie's disease with tamoxifen.
    Ralph DJ; Brooks MD; Bottazzo GF; Pryor JP
    Br J Urol; 1992 Dec; 70(6):648-51. PubMed ID: 1486392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study.
    Rehman J; Benet A; Melman A
    Urology; 1998 Apr; 51(4):620-6. PubMed ID: 9586617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards an evidence-based understanding of Peyronie's disease.
    Cavallini G
    Int J STD AIDS; 2005 Mar; 16(3):187-94; quiz 94-5. PubMed ID: 15829017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intralesional hyaluronic acid: an innovative treatment for Peyronie's disease.
    Gennaro R; Barletta D; Paulis G
    Int Urol Nephrol; 2015 Oct; 47(10):1595-602. PubMed ID: 26257044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it effective?
    Carson CC
    Tech Urol; 1997; 3(3):135-9. PubMed ID: 9422444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study.
    Fitch WP; Easterling WJ; Talbert RL; Bordovsky MJ; Mosier M
    J Sex Med; 2007 Mar; 4(2):477-84. PubMed ID: 17367443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intralesional Injection of Interferon-α2b Improves Penile Curvature in Men with Peyronie's Disease Independent of Plaque Location.
    Stewart CA; Yafi FA; Knoedler M; Mandava SH; McCaslin IR; Sangkum P; Sikka S; Trost L; Hellstrom WJ
    J Urol; 2015 Dec; 194(6):1704-7. PubMed ID: 26144333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study.
    Inal T; Tokatli Z; Akand M; Ozdiler E; Yaman O
    Urology; 2006 May; 67(5):1038-42. PubMed ID: 16581113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.